Processes for the production of alpha-difluoromethyl ornithine (DFMO)
申请人:Bristol-Myers Squibb Company to Women First HealthCare, Inc.
公开号:US20030083384A1
公开(公告)日:2003-05-01
Provided are processes and synthetic intermediates useful for the preparation of &agr;-difluoromethylornithine (DFMO) having the formula
1
提供了用于制备α-二氟甲基鸟氨酸(DFMO)的过程和合成中间体,其化学式为1。
[EN] IDENTIFICATION OF NSC23925 ISOMERS TO REVERSE MULTIDRUG RESISTANCE IN HUMAN CANCERS<br/>[FR] IDENTIFICATION D'ISOMÈRES NSC23925 POUR INVERSER LA RÉSISTANCE MULTIPLE AUX MÉDICAMENTS DANS DES CANCERS HUMAINS
申请人:GEN HOSPITAL CORP
公开号:WO2013126664A1
公开(公告)日:2013-08-29
This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same.
Identification of NSC23925 Isomers to Reverse Multidrug Resistance in Human Cancers
申请人:THE GENERAL HOSPITAL CORPORATION
公开号:US20140371165A1
公开(公告)日:2014-12-18
This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same.
PROCESSES FOR THE PRODUCTION OF ALPHA-DIFLUOROMETHYL ORNITHINE (DFMO)
申请人:Skinmedica, Inc.
公开号:EP1421058B1
公开(公告)日:2010-05-05
Compounds For Reducing Drug Resistance And Uses Thereof
申请人:Duan Zhenfeng
公开号:US20120035126A1
公开(公告)日:2012-02-09
This invention provides compounds capable of reducing drug resistance in a subject undergoing cancer treatment, methods using the compounds, compositions, and methods for identifying such compounds.